Phase 1 Study to Evaluate MEDI4736 in MDS | Aplastic Anemia & MDS International Foundation
Phase 1 Study to Evaluate MEDI4736 in MDS

Clinical Trial: NCT02117219

For more details on this clinical trial, including contact information, please see this trial’s listing on

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 [PD-L1]) to evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 monotherapy and MEDI4736 in combination with azacitidine in adult patients with myelodysplastic syndrome.

Study Date: 
Thu, 05/01/2014 to Thu, 06/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Biological: MEDI4736 MEDI4736 will be administered by IV infusion Other Name: durvalumab Drug: VIDAZA VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy Other Name: azacitidine